⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 8, 2024Deleted JournalOpen Access

Aflibercept in a real-world setting: the AURIGA study

J Wachtlin Hakan Kaymak Hans Hoerauf Helmut Allmeier Tobias Machewitz Paula Scholz Markus Schürks Nicolas Feltgen

View Full Paper

Ask AI

Bookmark

Share

Abstract

AURIGA is the largest prospective real-world study to evaluate intravitreal aflibercept 2 mg (IVT-AFL) treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) and diabetic macular edema. Here we present the 24-month data from the German cohort of treatment-naïve patients with ME due to RVO.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wachtlin et al. (2024) studied this question.

synapsesocial.com/papers/68e61188b6db6435875a3fb7 https://doi.org/10.1007/s00347-024-02051-3

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Clinical improvements at Week 36 sustained to Week 64 with aflibercept 8 mg in macular edema following retinal vein occlusion, with significantly fewer injections compared to aflibercept 2 mg: Results from the QUASAR trialHuman Clinical Trial · 2026
2Evaluation of intravitreal aflibercept injected alone against aflibercept with triamcinolone acetonide for management of macular edema secondary to retinal vein occlusionOriginal Research · 2026
3Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the apex studyOriginal Research · 2026
4The Efficacy and Safety of Intravitreal Aflibercept 8 mg in Clinical Practice2025 · 4 citations
5Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU®) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective AnalysisCohort Study · 2026